AstraZeneca
AstraZeneca Cancels £450 Million UK Vaccine Plant Expansion Amid Government Funding Reduction
AstraZeneca, vaccine manufacturing, UK investment, government funding, Labour administration, economic growth, pharmaceutical industry
Enhertu Secures 7th FDA Approval for Expanded Use in HER2-Low and HER2-Ultralow Breast Cancer
Enhertu, FDA Approval, HER2-Low, HER2-Ultralow, Breast Cancer, AstraZeneca, Daiichi Sankyo
AstraZeneca Invests $570M in Canadian Expansion, Creating 700 New Jobs
AstraZeneca, Canadian expansion, $570M investment, 700 new jobs, life sciences, R&D, clinical trials, pharmaceutical industry
AstraZeneca Secures Full FDA Approval for Lymphoma Treatment Selected by CMS
AstraZeneca, FDA Approval, Lymphoma Treatment, CMS-Selected
AstraZeneca’s Calquence Gains FDA Approval as First-Line Treatment for Mantle Cell Lymphoma
AstraZeneca, Calquence, acalabrutinib, BTK inhibitor, mantle cell lymphoma, first-line treatment, FDA approval
J&J’s Rybrevant Combination Therapy Outperforms AstraZeneca’s Tagrisso in Lung Cancer Survival Trial
J&J, Rybrevant, AstraZeneca, Tagrisso, lung cancer, NSCLC, survival trial, combination therapy
AstraZeneca’s Tagrisso Expands EU Approval for NSCLC Treatment
AstraZeneca, Tagrisso, NSCLC, EU approval, EGFR mutations, lung cancer treatment
FDA Declines Approval for J&J’s Subcutaneous Rybrevant and AstraZeneca’s Full Approval Bid for Andexxa
FDA, J&J, Rybrevant, AstraZeneca, Andexxa, regulatory review, pharmaceuticals
FDA Rejects Full Approval for AstraZeneca’s Andexxa Amid Safety Concerns
Andexxa, AstraZeneca, FDA, full approval, safety concerns, bleeding reversal agent, FXa inhibitors
Advancements in BTK Inhibitors for Chronic Lymphocytic Leukemia: A Comparative Analysis of AstraZeneca, Eli Lilly, and BeiGene Therapies
BTK inhibitors, Chronic Lymphocytic Leukemia (CLL), AstraZeneca, Eli Lilly, BeiGene, Acalabrutinib, Ibrutinib, Zanubrutinib, Pirtobrutinib, Nemtabrutinib, Fixed-duration therapy, Continuous therapy, Efficacy, Safety